Expensify Inc vs Herbalife Nutrition Ltd — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B). The key difference: Herbalife Nutrition Ltd is far larger — about 6.4× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Herbalife Nutrition Ltd for 43 Days on average.
| EXFY | HLF | |
|---|---|---|
Market Cap | $208.82M | $1.34B |
Volume | 456,102 | 1,589,457 |
Sector | Technology | Consumer Staples |
52-Week High | $2.72 | $19.96 |
52-Week Low | $0.75 | $7.75 |
Typical Hold Time | 41 Days | 43 Days |
Enterprise Value | $148.44M | $3.18B |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% today, showing technical bullish momentum with positive moving average signals. The company reported mixed Q2 2026 results with revenue of $33.9M and improved profitability, beating EPS estimates. Recent developments include AI-native ERP integrations and European card expansion, though fundamentals show negative net margins and high P/E ratio of 258.82. Analyst consensus is bullish with a $13.75 price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with strong analyst optimism contrasting with fundamental challenges. The stock's substantial discount to consensus target offers potential upside, but investors must weigh improving cash flow trends against persistent negative profitability and competitive pressures in the expense management sector.
HLF trades at $12.82, up 1.34% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue has been stable around $5.0B annually, with a net income margin of 4.53% in 2025. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.
The stock appears undervalued with a P/E of 8.22 and P/S of 0.26, supported by a 53.84% analyst buy rating and a $19.00 consensus price target. Key risks include high debt levels, with total liabilities at $3.53B, and inconsistent earnings performance. Positive cash flow trends in 2026 projections and margin expansion plans offer potential upside, but investor caution is warranted due to ongoing leadership changes and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →